Human observational studies link sarcopenic obesity with frailty and cognitive impairment, and with higher mortality in dialysis patients. A human trial reports reduced sarcopenic obesity with semaglutide; a power-training trial reports improvement in older women with sarcopenic obesity. A study following major abdominal cancer surgery finds no clear link with postoperative complications.
952 findings in 550 papers from 2004 to 2026, 82 of them since April 2026
“At discharge, 80 patients (42.55%) were no longer classified as sarcopenic and showed significant improvements in HGS.”
Power training decreases sarcopenic obesity in older women with sarcopenic obesity (35.7% reversal).
“Notably, 35.7% of the participants in the PT group (n = 5) achieved normalization of the key parameters—muscle mass, strength, and BMI—indicating full reversal of the SO condition.”
Human trialin older women with sarcopenic obesity32 weeksn = 5
Androgen deprivation therapy induces sarcopenic obesity in humans (prostate cancer).
“Although ADT contributes substantially to disease control, it also induces significant adverse metabolic and body composition changes. These alterations include loss of lean mass, increased fat mass, and deterioration in muscle quality”
Mifepristone induces sarcopenic obesity in mice (bilateral orchiectomy).
“chronic mifepristone administration induced obese sarcopenia, hepatic steatosis and insulin resistance, accelerated thymus aging, but prevented bone loss in male mice.”
Animalsbilateral orchiectomy30 mg/kg every other day28 daysmales
Cholecalciferol showed no clear effect on sarcopenic obesity in humans (overweight older adults) (3.7% in LDG vs. 0.9% HDG, p = 0.18).
“no significant differences were noted in the proportion of patients with SO at study entry (1.8% in LDG vs 1.6% HDG; p = 0.99) and at 12 months (3.7% in LDG vs. 0.9% HDG; p = 0.18) across arms.”
Human trialoverweight older adults3750 IU/day vs 600 IU/day12 monthsn = 248
Sarcopenic obesity is linked with worse physical function in humans (p = 0.022 to p < 0.001).
“Regardless of definition, participants with sarcopenic obesity were older; had lower walking speed, grip strength, and balance; and exhibited higher prevalence of conventional sarcopenia, knee osteoarthritis, and reduced mobility function”
Sarcopenic obesity impairs quality of life in humans.
“Sarcopenic obesity, or the loss of muscle mass and function associated with excess adiposity, is a largely untreatable medical condition associated with diminished quality of life”
Sarcopenic obesity is linked with lower handgrip strength in sufficiently active older adults (ꞵ = -0.210, p < 0.05).
“Multiple linear regression showed that SO negatively explained the variability of handgrip strength (model 2: ꞵ=-0.210; p < 0.05), even when adjusted for confounding variables.”
Sarcopenic obesity is linked with worse activities of daily living in humans (post-acute rehabilitation after stroke) (β = −0.048, p = 0.031).
“In multivariate analyses, sarcopenic obesity was independently and negatively associated with FIM-motor (β = −0.048, p = 0.031) and FILS at discharge (β = −0.095, p = 0.046) in women.”
Humanspost-acute rehabilitation after strokefemalesn = 352
Sarcopenic obesity is linked with worse memory in humans (SO defined by waist-to-hip-to-height ratio, mean annual change) (adjusted β -0.09 (95% CI -0.14 to -0.05)).
“associations of SO defined by waist-to-hip-to-height ratio (WHHR) appeared to be the strongest (-0.36 [-0.50 to -0.22], -0.31 [-0.45 to -0.17], -0.09 [-0.14 to -0.05] and -2.70 [-3.81 to -1.59])”
HumansSO defined by waist-to-hip-to-height ratio, mean annual change
Journal of the American Medical Directors Association·
Inflammation
↑upin humans2
2 studies
Sarcopenic obesity is linked with higher inflammation in humans (COPD).
“had more pronounced inflammaging according to the neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and systemic inflammatory index”
Hemoglobin is linked with sarcopenic obesity in humans (indirect effect on the sleep duration–sarcopenic obesity relationship (mediation analysis)) (indirect effect -1.20 × 10−3 (95%CI -2.20 × 10−3 to 3.30 × 10−4); 11.01% of total effect).
“Hemoglobin had an indirect effect on the relationship between sleep duration and SO, accounting for 11.01% of the total effect variation”
Humansindirect effect on the sleep duration–sarcopenic obesity relationship (mediation analysis)
Hepatic steatosis index is linked with sarcopenic obesity in humans (mediating the association between DI-GM and sarcopenic obesity) (17.8%, p < 0.05).
“17.8% of the association between DI-GM and SO was mediated by HSI (p < 0.05)”
Humansmediating the association between DI-GM and sarcopenic obesityn = 3,746
sex showed no clear effect on sarcopenic obesity in humans (elderly men and women) (10% in both men (95% CI: 8%-12%) and women (95% CI: 8%-12%)).
“A similar result was observed after stratification by sex, with a prevalence of 10% in both men (95% CI: 8%-12%; I2: 97.46%, p<0.001) and women (95% CI: 8%-12%; I2: 98.72%, p<0.001).”
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·
Sarcopenic obesity is linked with a higher risk of mortality in humans (late follow-up period) (HR 3.75, 95% CI 1.66-8.50, p = 0.002).
“JWGSO-defined sarcopenic obesity was not significantly associated with mortality in the early follow-up but was linked to increased mortality risk in the late period (HR 3.75, 95% CI 1.66-8.50, p = 0.002).”
Sarcopenic obesity is linked with a higher risk of mortality in humans following major abdominal cancer surgery (HR 6.44, 95% CI 2.45-16.92, p < 0.001).
“SO patients experienced significantly increased short-term mortality at 30 days (HR 6.44, 95% CI 2.45-16.92, p < 0.001∗)”
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·
Sarcopenic obesity is linked with a higher risk of mortality in humans (esophageal cancer undergoing curative treatment) (HR 2.47, 95% CI 1.39–4.37, p = 0.002).
“Only the combination of both, sarcopenic obesity was significantly associated in multivariable analysis (HR 2.47, 95 %CI 1.39; 4.37, p = 0.002)”
Humansesophageal cancer undergoing curative treatmentn = 145
Sarcopenic obesity is linked with a higher risk of mortality in cancer patients (adjusted HR 1.368, 95% CI 1.107-1.690).
“cancer patients with SO were significantly associated with a higher risk of all-cause mortality (adjusted HR 1.368, 95%CI 1.107-1.690) compared with individuals without SO”
Sarcopenic obesity predicts mortality in humans (compared to patients with non-sarcopenic non-obesity phenotype) (HR: 2.78, 95% CI 1.57-4.94; P = 0.001).
“all-cause mortality (hazard ratio[HR]: 2.78, 95% CI 1.57-4.94; P = 0.001)”
Humanscompared to patients with non-sarcopenic non-obesity phenotype3 yearsn = 487
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·
Sarcopenic obesity is linked with a higher risk of cardiovascular disease in humans (elderly patients with T2DM, SO classified using BF%) (HR = 6.02, 95% CI = 1.56-23.15).
“SO classified using BF% was significantly associated with the primary endpoint [hazard ratio (HR) = 2.94, 95% CI = 1.25-6.92] and incident CVD (HR = 6.02, 95% CI = 1.56-23.15)”
Humanselderly patients with T2DM, SO classified using BF%3.46 ± 1.15 yearsn = 386
Sarcopenic obesity is associated with frailty in humans (patients with obesity) (OR 3.30, 95% CI 1.38-7.92).
“SO, diagnosed by BIA and US, was independently associated with frailty regardless of confounding factors (odds ratio: 3.30, 95% confidence interval [CI]: 1.38-7.92”
Sarcopenic obesity is associated with frailty in humans (B 0.074, 95% CI 0.05-0.1, p < 0.001).
“SO (B 0.074, 95% C.I. 0.05-0.1, p < 0.001) and pre-sarcopenia (without obesity B 0.03, 95% C.I, 0.007-0.044, p < 0.001, with obesity B 0.11, 95% C.I. 0.05-0.16, p < 0.001) were associated with frailty.”
Sarcopenic obesity is associated with frailty in humans (locomotive syndrome stage 1) (OR 4.25, 95% CI 1.34 to 13.5).
“The odds ratios for frailty risk compared to normal were 3.97 (95% confidence interval (CI): 1.51 to 10.4), 1.71 (95% CI: 0.55 to 5.39), and 4.25 (95% CI: 1.34 to 13.5) for sarcopenia (RT2), obesity, and sarcopenic obesity subtypes, respectively”
Sarcopenic obesity is linked with a higher risk of frailty in older adults with diabetes.
“SO was further linked to increased risk of falls, frailty, and various levels of activities of daily living (ADL) and instrumental activities of daily living (IADL) disabilities”
Journal of the Formosan Medical Association = Taiwan yi zhi·
Sarcopenic obesity is associated with hypertension in humans (67.74% vs others).
“SO patients had a significantly higher burden of comorbidities, including hypertension (67.74%), diabetes mellitus (70.97%), and hypothyroidism (35.48%)”
Hypertension is linked with a higher risk of sarcopenic obesity in humans (hospitalized older adults) (OR = 2.094, p = 0.007).
“Independent predictors of SO included older age (OR = 1.064, p = 0.002), female gender (OR = 3.574, p < 0.001), hypertension (OR = 2.094, p = 0.007), and diabetes mellitus (OR = 3.342, p < 0.001).”
Sarcopenic obesity is linked with a higher risk of hypertension in humans (community population) (HR 1.61 (95% CI 1.09–2.37), p = 0.017).
“sarcopenic obesity were associated with hypertension; hazard ratios (HRs) and 95% confidence intervals (CIs) were 1.67 (1.43 ~ 1.96), p < 0.001, and 1.61 (1.09 ~ 2.37), p = 0.017”
Sarcopenic obesity is associated with hypertension in adults aged >= 60 years (56.04% vs 38.93%; P < 0.01).
“prevalence of cardiovascular disease (15.38% vs 6.59%; P < 0.01), hypertension (56.04% vs 38.93%; P < 0.01), and stroke (7.69% vs 2.25%; P < 0.01) was also significantly higher in the SO group”
Physical activity is associated with sarcopenic obesity in obese T2DM patients.
“SO was significantly associated with older age, low physical activity, poor glycemic control, insulin use, and the presence of diabetes complications.”
Physical activity is associated with sarcopenic obesity in humans (> 3032 kcal/week for men and 2730 kcal/week for women).
“A total physical activity energy expenditure of > 3032 kcal/week (433 kcal/day) for men and 2730 kcal/week (390 kcal/day) for women was associated with a reduced prevalence of SO.”
Humans> 3032 kcal/week (433 kcal/day) for men and 2730 kcal/week (390 kcal/day) for womenn = 2,071
Physical activity is linked with a lower risk of sarcopenic obesity in humans.
“The likelihood of central obesity and sarcopenic obesity decreased in groups with recommended PA levels, regardless of whether energy intake met or did not meet the average requirement.”
Diabetes mellitus is linked with a higher risk of sarcopenic obesity in fully adjusted models for 1-year SO deterioration (OR = 4.01, 95% CI: 1.07-15.12).
“In fully adjusted models, hypertension (OR = 3.67, 95% CI: 1.26-10.66) and diabetes (OR = 4.01, 95% CI: 1.07-15.12) were independent predictors of SO deterioration.”
Humansin fully adjusted models for 1-year SO deterioration1 yearn = 1,048
Journal of the Formosan Medical Association = Taiwan yi zhi·
Diabetes mellitus is linked with a higher risk of sarcopenic obesity in humans (hospitalized older adults) (OR = 3.342, p < 0.001).
“Independent predictors of SO included older age (OR = 1.064, p = 0.002), female gender (OR = 3.574, p < 0.001), hypertension (OR = 2.094, p = 0.007), and diabetes mellitus (OR = 3.342, p < 0.001).”
Diabetes mellitus is linked with a higher risk of sarcopenic obesity in humans (sarcopenic obesity).
“diabetes mellitus (β = 3.074, p < 0.001) were identified as significant risk factors for SO, with diabetes increasing the risk approximately threefold.”
Sarcopenic obesity is linked with a higher risk of diabetes mellitus in humans (OR = 2.21, 95 % CI: 1.72-2.84).
“Participants with sarcopenia obesity exhibit a higher risk of diabetes than those with obesity or sarcopenia alone (CNHS, OR = 2.21, 95 %CI:1.72-2.84”
Diabetes mellitus is associated with sarcopenic obesity in humans.
“diabetes, hypertension, osteoporosis, depression, mild cognitive impairment, a fall history, frailty, and metabolic syndrome among the disease factors”
Sarcopenic obesity is associated with falls in the type 2 diabetes group, compared with the robust group.
“In the T2D group, sarcopenic obesity was associated with lower physical QOL, reduced physical activity, slow gait speed, and a high incidence of falls compared with the robust group.”
Humansin the type 2 diabetes group, compared with the robust groupn = 527
Sarcopenic obesity is linked with a higher risk of falls in early-onset type 2 diabetes patients, characterized by visceral fat area (HR 3.98, 95% CI 2.57-6.16).
“EOT2D patients with sarcopenic obesity, particularly characterized by visceral fat area (VFA), demonstrated a substantially higher fall risk (HREOT2D+SO-VFA = 3.98; 95% CI: 2.57-6.16)”
Humansin early-onset type 2 diabetes patients, characterized by visceral fat area
Sarcopenic obesity is linked with a higher risk of falls in older adults with diabetes.
“SO was further linked to increased risk of falls, frailty, and various levels of activities of daily living (ADL) and instrumental activities of daily living (IADL) disabilities”
Sarcopenic obesity is linked with a higher risk of falls in humans (compared with men with neither sarcopenia nor obesity) (incident rate ratio: 1.59, 95% CI: 1.03-2.44).
“higher 12-month incident falls rates (incident rate ratio: 1.59, 95% CI: 1.03-2.44) than men with neither sarcopenia nor obesity.”
Humanscompared with men with neither sarcopenia nor obesity12 monthsmalesn = 1,416
Sarcopenic obesity raises the risk of falls in humans.
“Sarcopenic obesity is becoming increasingly prevalent among older adults and may contribute to greater risk of functional decline, falls, fractures and mortality than sarcopenia or obesity alone.”
Sarcopenic obesity is associated with cognitive impairment in humans (at diagnosis I) (OR 2.3, 95% CI 1.4-3.8, P = 0.007).
“Significant associations between SO and cognitive impairment were observed in individuals aged 60-85 at diagnosis I (OR: 2.3, 95%CI 1.4-3.8, P = 0.007)”
Sarcopenic obesity is linked with a higher risk of cognitive impairment in humans (patients requiring maintenance hemodialysis) (OR 1.47, 95% CI 1.11-1.96).
“The association between SO and CI was weakened but remained statistically significant after adjusting for age, sex, and educational status (odds ratio, 1.47; 95% CI, 1.11-1.96).”
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·
Sarcopenic obesity raises the risk of cognitive impairment in humans (compared with non-SO) (OR 3.46, 95% CI 2.24-5.32).
“compared with non-SO, SO increased the prevalence of cognitive impairment (k = 3; odds ratio [OR] = 3.46; 95% CI: 2.24-5.32; high certainty of evidence)”
Exercise is linked with a lower risk of sarcopenic obesity in humans (p < 0.01).
“those exercising ≥ 3 times/week were less likely to have obesity, sarcopenia, and sarcopenia obesity in all groups (p < 0.01), except for sarcopenia in older males and females (p > 0.05).”
Exercise is associated with sarcopenic obesity in humans (17% (95% CI: 8-29%)).
“Subgroup analysis according to lifestyle factors demonstrated that the SO prevalence was 17% (95% CI: 8-29%, I2 = 99.5%, P < 0.01) in older adults without exercise habits.”
“According to accumulating data, exercise can increase the release of myokines from diverse tissues into the blood and postpone the SO onset and progression”
Sarcopenic obesity is linked with a higher risk of type 2 diabetes in humans (normoglycaemia) (HR = 2.11; 95% CI: 1.10-4.04).
“participants with sarcopenic obesity, but not sarcopenia only or obesity only, exhibited a higher risk of progression from normoglycaemia to diabetes (HR = 2.11; 95% CI: 1.10-4.04)”
Multidisciplinary weight-loss program lowers the risk of sarcopenic obesity in patients with sarcopenic obesity at admission (42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic).
“At the end of the multidisciplinary program, 42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic (No SO discharge), while for 108 patients, the SO condition was unchanged (SO discharge).”
Human trialin patients with sarcopenic obesity at admission4 weeksn = 188
Sarcopenic obesity is associated with frailty and disability in human observational studies, cognitive impairment in community-dwelling older adults, and higher mortality in dialysis patients. A trial reports reversal with power training in older women, while trials of semaglutide and a multidisciplinary weight-loss program report reductions in sarcopenic obesity.
Human studies link sarcopenic obesity to frailty, falls, disability and cognitive impairment, while dialysis cohorts associate it with higher mortality. A human trial reports reduced sarcopenic obesity with semaglutide; a trial in older women reports a reduction with power training.
Human studies associate sarcopenic obesity with frailty, declining physical performance, cardiometabolic disease, and PhenoAge acceleration. After major abdominal cancer surgery, a human study links it to longer hospital stays and higher mortality but reports no increase in postoperative complications.
Summary rewritten as its findings changed.
As it read before
Human studies link sarcopenic obesity to impaired cognition, memory, and attention, higher C-reactive protein, altered lipid profiles, and urinary incontinence in females. Reviews also associate it with mortality, cardiovascular disease, and altered physical function, while exercise reduces risk in menopausal females.
Obesity with poor muscle health was linked to 2.54 times the odds of developing knee arthritis with symptoms over six years compared with people with obesity alone.Obesity with poor muscle health was linked to 2.54 times the odds of developing knee arthritis with symptoms over six years compared with people with obesity alone.
Equations developed in 38,542 UK Biobank participants helped assess 168,875 adults at high risk of obesity accompanied by low muscle mass and strength.Equations developed in 38,542 UK Biobank participants helped assess 168,875 adults at high risk of obesity accompanied by low muscle mass and strength.
Accepted, not yet published: cohort · 168,875 peopleBiomarkers
Who was studied168,875 middle-aged and older adults, against other strategies
What changedThe new sarcopenic obesity definition showed better diagnostic and prognostic performance than other strategies, with higher risks of most adverse outcomes
The catchBaseline-defined sarcopenic obesity showed low sensitivity (0.296) against imaging DXA-defined sarcopenic obesity
Muscle mass in the arms and legs rose 0.70 kg with high-intensity intervals versus 0.11 kg with moderate continuous exercise over 12 weeks.Muscle mass in the arms and legs rose 0.70 kg with high-intensity intervals versus 0.11 kg with moderate continuous exercise over 12 weeks.
Female mice fed a high-fat diet for seven months developed obesity, but signs of metabolic exhaustion tracked differences in muscle dysfunction rather than obesity…Female mice fed a high-fat diet for seven months developed obesity, but signs of metabolic exhaustion tracked differences in muscle dysfunction rather than obesity severity.